Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
| Autor: | Faezeh Hosseinzadeh, Iman Seyhoun, Jafar Ai, Benyamin Parseh, Zeinab Ghazvinian, Javad Verdi, Shahrokh Abdolahi, Milad Mirmoghtadaei, Mahdi Shadnoush, Seyed Moein Seyhoun, Saieh Hajighasemlou |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Sorafenib HepG2 Carcinoma Hepatocellular urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols medicine Humans heterocyclic compounds neoplasms IC50 Mesenchymal stem cell Cell Proliferation Cell growth business.industry Liver Neoplasms Drug Synergism Mesenchymal Stem Cells hepatocellular carcinoma Hep G2 Cells General Medicine HCCS medicine.disease female genital diseases and pregnancy complications digestive system diseases 030104 developmental biology Cell culture 030220 oncology & carcinogenesis Hepatocellular carcinoma Toxicity Cancer research business Research Article medicine.drug |
| Zdroj: | Asian Pacific Journal of Cancer Prevention : APJCP |
| ISSN: | 2476-762X |
| Popis: | Objective: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. Methods: HepG2 cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare the inhibition of cell growth between the two groups with different treatments. Results: The combination treatment of cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib alone (3.4 vs. 2.7 respectively). Conclusion: This study suggests that a combination of sorafenib with MSC-CM can synergistically suppress the growth of HCC cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|